Thorolfsdottir, R. B., Sveinbjornsson, G., Hjorleifsson Eldjarn, G., Aegisdottir, H. M., Styrkarsdottir, U., Gretarsdottir, S., Steinthorsdottir, V., Tragante, V., Oddsson, A., Stefansdottir, L., Thorleifsson, G., Einarsson, G., Helgason, H., Jonsdottir, A. B., Gudjonsson, S. A., Ferkingstad, E., Brunak, S., Brøns, N., Bundgaard, J. S. ... DBDS Genomic Consortium (2026).
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.
Human Molecular Genetics,
35(2), Article ddaf177.
https://doi.org/10.1093/hmg/ddaf177
Garitaonaindia, Y., Khan, S.
, Friis, R., Kjær, S., Borch, T. H., Ruhlmann, C.
, Guldbrandt, L. M., Luczak, A. A.
, Schmidt, H., Bastholt, L., Svane, I. M., Donia, M. & Ellebaek, E. (2026).
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.
Journal of the National Cancer Institute,
118(2), 261-268.
https://doi.org/10.1093/jnci/djaf263